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Background: This study reports secular trends in medicine use for headache among adolescents in 20 countries
from 1986 to 2010. Methods: The international Health Behaviour in School-aged Children (HBSC) survey includes
self-reported data about medicine use for headaches among nationally representative samples of 11-, 13- and 15-
year-olds. We included 20 countries with data from at least three data collection waves, with a total of 380 129
participants. Results: The prevalence of medicine use for headaches varied from 16.5% among Hungarian boys in
1994 to 62.9% among girls in Wales in 1998. The prevalence was higher among girls than boys in every country
and data collection year. The prevalence of medicine use for headaches increased in 12 of 20 countries, most
notably in the Czech Republic, Poland, Russia, Sweden and Wales. Conclusion: The prevalence of medicine use for
headaches among adolescents is high and increasing in many countries. As some medicines are toxic this may
constitute a public health problem.
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Introduction
Medicine use for headaches is common among adolescents.
1–3
Unsupervised medicine use for headaches in adolescents can
be problematic: Some adolescents misuse prescription drugs as they
know little about medicines for headaches4,5 and they may use
headache medicines inappropriately, e.g. to treat general
discomfort.6,7 A qualitative study based on interviews with parents
of children under 5 years old suggests that due to time pressures in
modern families, medicines are often readily given to children by
their parents in order to quickly mitigate pain-related discomfort.8
Use of common over-the-counter (OTC) pain killers are often
reported by children and adolescents attempting suicide.9
Medicine use for aches in adolescence is predictive of medicine
use in young adulthood, i.e. inappropriate medicine use may
continue or increase over the life course.10 It seems necessary to
promote appropriate use of medicines among adolescents.
Therefore, it is important to know the prevalence, demographic
patterns and secular trends of medicine use.
It is difficult to get appropriate data since sales statistics do not
indicate user characteristics and prescription studies do not include
OTC medicines. Self-reported use is potentially the most appropri-
ate data source for analysis of prevalence and trends in medicine use
for headache.11–13
There are few studies about time trends in adolescents’ medicine
use for headaches. Reports from Spain and Denmark showed
increasing use of painkillers over the past two decades.13,14 Data
from the USA showed no major changes over time in the use of
painkillers.11 The Spanish study13 focused on the age group 0–15
and included data from parents about their children’s use of specific
drugs. The Danish study14 used data from 11- to 15-year-olds about
medicine use for headache. The American study11 focused on 0- to
12-year-olds and collected data from parents about use of specific
drugs. These few available studies are difficult to compare because of
differences in study population, data collection and measurements.
Many factors such as need for medication, increased marketing,
increased availability, and changing norms about medicine use
may result in increasing trends in medicine use. Allotey et al.7
suggest that there is an increasing propensity to turn to
medication as a possible way of improving lifestyle. They interpret
the findings as a progressive medicalization of present day society.
We have not been able to find systematic information about these
issues and are hesitant to formulate specific hypotheses about time
trends in adolescents’ medicine use for headache.
The objective of this article is descriptive: to present international
secular trends in adolescent boys’ and girls’ self-reported medicine
use for headaches over an extended period from 1986 to 2010. The
study is about medicine use behaviour, not specific drugs or active
ingredients. The international Health Behaviour in School-aged
Children (HBSC) study provides a unique opportunity to study
secular trends in adolescents’ self-reported use of medicine for
headache.
Methods
The HBSC study comprises cross-sectional surveys carried out every
4 years in the participating countries.15 HBSC uses a standardized
protocol for sampling students in three age groups (11-, 13- and
15-year-olds) in nationally representative samples of schools. The
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three waves of data collection in 20 countries (see table 1,
n = 380 129), among 13- and 15-year-old girls and boys. The
response rate varied by country but was generally high, over 70%.
Students answered the internationally standardized HBSC ques-
tionnaire during a class period. The participants received oral and
written information about the study and were informed that par-
ticipation was voluntary and anonymous. In each country, the study
complied with national research ethical and data protection
regulations.16
Medicine use was measured by the following survey item: ‘Within
the past month, did you take any pills or medicine for headache?’ In
the first two waves of data collection 1987–88 and 1993–94, the
response categories were ‘yes’ and ‘no’. In the last three waves of
data collection 1997–98, 2005–06 and 2009–10, the response
categories were ‘no’, ‘yes once’ and ‘yes several times’, probably in
order to study adolescents with frequent medicine use. The item was
not included in 2001–02. There is little available information about
the validity of adolescents’ self-reported medicine use. One study
asked both adolescents and their parents about medicine use for
headache in the past month. The agreement between the two
parties was fairly high, gamma correlation = 0.67, Kappa
coefficient = 0.41.17
We dichotomized the responses into no and yes. The proportion
of missing responses was less than 4.5% in all countries and all data
collection waves with only two exceptions where the proportion of
missing was 7.7 and 8.8%. We included missing in the no category to
avoid inflated prevalence rates. Three countries have data from six
data collection waves, four countries from five waves, four countries
from four waves and nine countries from three waves of data
collection (table 1).
Statistical procedures included contingency tables and the
Cochran–Armitage test for trend.18 This test is based on the
regression coefficient for a weighted linear regression of a
binomial proportion of a variable (here: prevalence of medicine
use for headache) on an explanatory variable (here: year of data
collection). Tests for trends only included years of data collection
with data about medicine use. All tests were stratified by gender and
age group
Results
Table 2 shows that the prevalence of medicine use for headache
varied substantially across country, gender and data collection
wave. For instance, in the 2009–10 waves of data collection, the
lowest prevalence was among boys in Austria (25.6%) and the
highest prevalence was among girls in France (55.8%). The
prevalence was higher for girls than boys in every country and
wave of data collection all P values from Chi-square tests were
under 0.01 with two exceptions: Germany in 2001 (P = 0.0919)
and Greenland in 1998 (P = 0.1666).
There was an increase in medicine use over time in 12 countries:
Austria, Czech Republic, Denmark, Finland (for boys but not girls),
France, Hungary, Latvia, Poland, Russia, Scotland, Sweden and
Wales. The increase was substantial—more than double among
girls in the Czech Republic and boys and girls in Hungary. In
three countries, Finland, Scotland and Sweden, the trend was not
linear but fluctuated over time. There was a decrease over time
among girls but not boys in Germany and among boys but not
girls in Greece. There was no clear increasing or decreasing trend
in eight countries: Canada, Finland (girls), Germany (boys), Greece
(girls), Ireland, Norway or Switzerland, and Flemish- and French-
speaking parts of Belgium. Secular trends were fairly similar for the
three age groups (data not shown).
Discussion
In 12 of the 20 countries, there was an increasing trend in the
prevalence of medicine use for headaches. In the remaining
countries, the prevalence was stable or characterized by increasing
and decreasing fluctuations. There was a more consistent increasing
pattern for girls than for boys. This comparative study confirms
prior studies which show different secular trends in use of
medicine for headache.11,13,14 There are no apparent geographic
patterns, nor specific time periods with more consistent increasing
patterns.
We have not been able to identify publications which provide a
sound explanation for the general increasing trend in adolescents’
Table 1 Study population by country and year of data collection
Country Year of data collectiona Total
1985–86 1989–90 1993–94 1997–98 2005–6 2009–10
Austria – 2982 5349 4316 4848 5033 22 528
Belgium (Flemish) – – 4506 4824 – 4180 13 510
Belgium (French) 3575 – 5196 2505 4476 4012 19 764
Canada – 5565 6758 6567 – – 18 890
Czech Republic – – 3585 3703 – 4425 11 713
Denmark – – 3912 5066 5741 4330 19 049
Finland 3216 2996 4187 4864 3410b 6723 25 396
France – – 4023 4133 7155 6160 21 471
Germany – – 3275 4792 7274 – 15 341
Greece – – – 4299 3715 4944 12 958
Hungary 4461 6498 5775 3609 – 4864 25 207
Ireland – – – 4394 4894 4965 14 253
Latvia – 3008 3818 3775 4245 4284 19 130
Norway 3955 5037 4952 5025 – – 18 969
Poland – 4613 4527 4861 – – 14 001
Russia – – 4001 3997 – 5174 13 172
Scotland 4760 3719 4959 5632 6190 6771 32 031
Sweden 2933 3553 3584 3802 4415 6718 15 005
Switzerland 4973 – – – 4621 6678 16 272
Wales 6338 6724 3870 4537 – – 21 469
Total 34 211 44 695 76 277 84 701 60 984 79 261 380 129
a: Items about medicine use were mandatory in the three first waves. The HBSC data collection in 2001–02 did not
include medicine use. The items about medicine use were optional in 2005–06 and 2009–10.
b: The data from Finland 2005–06 includes 13- and 15-year-olds but not 11-year-olds.






/eurpub/article/25/suppl_2/76/591376 by guest on 17 M
ay 2021
use of medicine for headache. The findings correspond with the
studies which suggest that increase in perceived stress,6 time
pressure in the families,7,8 and a general medicalization of the
society7 result in increasing medicine use. Other factors may
contribute to the increase in medicine use, e.g. a more aggressive
marketing of painkillers, higher availability, and changing norms
about medicine use. From a drug safety point of view, the results
of this study may be worrying. The findings may reflect an increasing
need for medication, but also changes in social norms and availabil-
ity resulting in an increase in medicine use. Further research is
needed to understand why medicine use for headaches has increased.
The main merit of this study is the large sample and representative
study population and the use of standardized and comparable data.
There are important limitations as well. The study does not include
information about specific drugs or active ingredients. Recent
studies suggest that the medicines used for headaches among ado-
lescents are mainly common OTC medicines such as acetamino-
phen/paracetamol, ibuprofen and acetylsalicylic acid.6,13,19 While
selection bias due to non-participating schools and pupils may be
a limiting factor, we have no means to carry out rigorous non-par-
ticipation analyses. It may be a limitation that the item about
medicine use for headache had two response categories until
1993–94 and three response categories from 1997–98 onwards. In
most of the countries with data from 1993–94 to 1997–98 there was
an increase in the prevalence of medicine use for headache, i.e. the
change of response categories may influence the findings. The
unknown validity of the medicine use measurement is an
important limitation of the study. The measurement includes
OTC medicine and may provide a more realistic representation of
medicine use in the general population than register-based studies
which only include prescription medicine.
Given the possible medicine use beyond indication, the potential
side effects and the modest knowledge among adolescents about
medicines,4 there is a need to promote appropriate medicine use.
In their comprehensive literature review, Hämeen-Anttila and Bush
concluded that children of the same age in different cultures appear
similar in their attitudes, beliefs and behaviour related to medicines
and they wish to learn about medicines.4 They proposed that health
educators and health care professionals should take a more active
role in educating children about rational medicine use.4
Both health education and sales restrictions are potential
components of future efforts to promote rational medicine use.20
Table 2 Prevalence (%) of 11-, 13- and 15-year-old boys and girls who used medicine for headache during the past month, including test for
trend
Country Sex Year of data collectiona Cochran-Armitage
testb
Difference between
first and last observation
1985–6 1989–90 1993–4 1997–8 2005–6 2009–10
Austria Boys – 18.9 20.5 26.8 27.0 25.6 * Up 6.7%
Girls – 27.8 27.9 31.4 33.9 32.7 * Up 4.7%
Belgium Flemish Boys – – 31.2 31.7 – 29.7 Down 1.5%
Girls – – 41.9 43.4 – 40.4 Down 1.5%
Belgium, French Boys 37.2 – 36.1 37.9 31.2 34.8 Down 2.4%
Girls 51.8 – 51.4 52.2 43.2 52.6 Up 0.8%
Canada Boys – 43.2 42.9 44.7 – – Up 1.5%
Girls – 58.1 57.8 58.0 – – Down 0.1%
Czech Republic Boys – – 15.4 22.6 – 27.8 * Up 12.4%
Girls – – 21.1 30.7 – 43.3 * Up 22.2%
Denmark Boys – – 28.7 34.1 35.3 35.1 * Up 6.4%
Girls – – 40.8 45.8 47.5 46.8 * Up 6.0%
Finland Boys 29.7 33.1 31.4 44.8 33.3c 32.9 * Up 3.2%
Girls 36.1 44.9 43.4 52.6 41.2c 42.3 Up 6.1%
France Boys – – 34.1 36.6 41.9 41.6 * Up 7.5%
Girls – – 48.4 51.8 53.6 55.8 * Up 7.4%
Germany Boys – – 20.5 24.1 19.5 – Down 1.0%
Girls – – 28.5 33.1 25.5 – * Down 3.0%
Greece Boys – – – 38.3 31.2 33.2 * Down 5.1%
Girls – – – 47.2 46.5 45.6 Down 1.6%
Hungary Boys 17.9 18.2 16.5 33.7 – 40.3 * Up 22.4%
Girls 25.1 26.9 27.6 42.7 – 50.3 * Up 25.2%
Ireland Boys – – – 42.7 38.3 40.3 Down 2.4%
Girls – – – 49.1 45.6 48.1 Down 1.0%
Latvia Boys – 24.6 21.8 29.2 34.9 39.0 * Up 14.4%
Girls – 36.5 34.2 39.2 50.1 49.6 * Up 13.1%
Norway Boys 22.7 24.0 25.3 24.7 – – Up 2.0%
Girls 35.2 34.2 35.0 34.6 – – Down 0.6%
Poland Boys – 18.8 17.5 29.1 – – * Up 10.3%
Girls – 26.3 28.5 42.4 – – * Up 16.1%
Russia Boys – – 18.2 30.1 – 35.4 * Up 17.2%
Girls – – 36.4 39.7 – 43.5 * Up 7.1%
Scotland Boys 34.0 37.3 35.2 48.7 37.9 38.5 * Up 4.5%
Girls 44.1 53.0 49.5 60.7 50.2 52.4 * Up 8.3%
Sweden Boys 28.1 32.1 36.1 33.8 35.2 39.7 * Up 11.6%
Girls 39.2 39.8 49.6 47.3 48.3 54.6 * Up 15.4%
Switzerland Boys 29.0 – – – 25.2 30.0 Up 1.0%
Girls 39.3 – – – 32.9 38.6 Down 0.7%
Wales Boys 34.9 40.7 42.5 45.6 – – * Up 10.7%
Girls 48.9 55.7 55.3 62.9 – – * Up 14.0%
a: The HBSC data collection in 2001–02 did not include medicine use.
b: Inclusion of data collection waves with data about medicine use.
c: The data from Finland 2005–06 includes 13- and 15-year-olds but not 11-year-olds.
Level of significance *P < 0.01.
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Parents, health educators, health professionals, health authorities
and the pharmaceutical industry are potential stakeholders of
future health promotion and control policies.20 From a research
point of view, we need better data about young people’s medicine
use and attitudes towards medicines. We also need insight into
individual, social and cultural forces that influence medicine use.
To conclude, this is the first study which reports systematic data
about time trends in adolescents’ use of medicine for headache in a
large number of countries. There was an increasing trend in 12
countries and inconsistent changes over time in 8 countries. There
was a more consistent increasing pattern for girls than boys.
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Key points
 This is the first report about time trends in adolescents’ use
of medicine for headache in a large number of countries.
 There was an increasing trend in 12 countries and inconsist-
ent changes over time in 8 countries.
 There was a more consistent increasing pattern for girls than
boys.
 There is a need to promote rational medicine use, e.g. by
means of health education and control policies such as sales
restrictions
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